SCHEMBL689476

SCHEMBL689476

CCOC(=O)c1c(-c2ccccc2Cl)csc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 9/20 0.67
GRM6 O15303 2/20 0.64
ALDH1A1 P00352 9/20 0.63
MAPT P10636 6/20 0.63
GAA P10253 2/20 0.63
KEAP1 Q14145 1/20 0.63
HSD17B10 Q99714 4/20 0.61
HPGD P15428 3/20 0.61
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
ALOX15 P16050 3/20 0.60
TDP1 Q9NUW8 2/20 0.60
MPI P34949 1/20 0.60
USP2 O75604 1/20 0.60
MAPK1 P28482 3/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
PRKCI P41743 2/20 0.57
NPSR1 Q6W5P4 2/20 0.53
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1553418 0.90 PRKCZ (0.64) PRKCZGRM6ALDH1A1MAPTGAA
SCHEMBL1554267 0.86 PRKCZ (0.69) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL8198873 0.85 ALDH1A1 (0.68) PRKCZGRM6ALDH1A1MAPTGAA
SCHEMBL8290591 0.85 PRKCZ (0.71) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL689530 0.84 PRKCZ (0.69) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL688430 0.83 PRKCZ (0.63) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL1190649 0.82 PRKCZ (0.80) PRKCZGRM6ALDH1A1MAPTGAA
SCHEMBL18342647 0.82 ALDH1A1 (0.60) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL689452 0.80 PRKCZ (0.80) PRKCZALDH1A1MAPTGAAKEAP1
SCHEMBL690269 0.80 PRKCZ (1.00) PRKCZALDH1A1MAPTGAAKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
EP-3749649-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
EP-1953148-B1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2012-02-29 EP disclosed
EP-1383463-B1 FUSED THIOPHENE COMPOUNDS AND USE THEREOF IN THE TREATMENT OF CHRONIC PAIN KING PHARMACEUTICALS INC (US) 2011-04-27 EP disclosed
US-7915267-B2 Heterocyclic amide compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-29 US disclosed
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed
EP-1383463-A4 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS INC (US) 2009-03-25 EP disclosed
US-7449490-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) 2008-11-11 US disclosed
EP-1953148-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-08-06 EP disclosed
US-7101905-B2 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2006-09-05 US disclosed
US-20060183921-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2006-08-17 US disclosed
EP-1383463-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE King Pharmaceuticals, Inc. (US) 2004-01-28 EP disclosed
US-20030073733-A1 Pharmaceutically active compounds and methods of use KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-04-17 US disclosed
WO-2002083083-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE KING PHARMACEUTICALS, INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183921-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE PRKCZ 3577/4885GRM6 203/4885ALDH1A1 1591/4885
US-20030073733-A1 Pharmaceutically active compounds and methods of use TRPV1, TPMT, ACHE PRKCZ 3577/4885GRM6 203/4885ALDH1A1 1591/4885
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH PRKCZ 4285/4885GRM6 2289/4885ALDH1A1 1977/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH PRKCZ 4285/4885GRM6 2289/4885ALDH1A1 1977/4885
US-20090137603-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF MMP2, MMP9, MMP1 PRKCZ 4810/4885GRM6 3799/4885ALDH1A1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.